JP6691971B2 - 慢性骨髄性白血病を治療又は寛解するための医薬組成物 - Google Patents
慢性骨髄性白血病を治療又は寛解するための医薬組成物 Download PDFInfo
- Publication number
- JP6691971B2 JP6691971B2 JP2018546319A JP2018546319A JP6691971B2 JP 6691971 B2 JP6691971 B2 JP 6691971B2 JP 2018546319 A JP2018546319 A JP 2018546319A JP 2018546319 A JP2018546319 A JP 2018546319A JP 6691971 B2 JP6691971 B2 JP 6691971B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- methyl
- acceptable salt
- amino
- myelogenous leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 title claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 36
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 title claims description 35
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 title claims description 35
- 150000003839 salts Chemical class 0.000 claims description 50
- VGGGPCQERPFHOB-RDBSUJKOSA-N (2s)-2-[[(2s,3r)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-RDBSUJKOSA-N 0.000 claims description 42
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 39
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 13
- 210000002700 urine Anatomy 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- -1 4-methyl-1-piperazinyl Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 4
- 229940000425 combination drug Drugs 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 33
- 229950009811 ubenimex Drugs 0.000 description 32
- 229940080856 gleevec Drugs 0.000 description 18
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 15
- 229960002411 imatinib Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 238000002648 combination therapy Methods 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229960003685 imatinib mesylate Drugs 0.000 description 4
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960001346 nilotinib Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940069905 tasigna Drugs 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000970901 Streptomyces olivoreticuli Species 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 229940045638 potassium citrate / sodium citrate Drugs 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940068117 sprycel Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(i)末梢血中の後骨髄球数が低下又は消失していること。
(ii)末梢血中の白血球数が低下していること。
(iii)末梢血中の好中球数が低下していること。
(iv)末梢血中の血小板数が低下していること。
(v)末梢血中の好中球数(N)とリンパ球数(L)の比(NLR)が低下していること。
(vi)末梢血中の血小板数(P)とリンパ球数(L)の比(PLR)が低下していること。
(vii)生存期間の延長(延命効果)が認められること。
実施例1:グリベック及びベスタチンの低用量・併用投与
71歳の女性の慢性骨髄性白血病患者に対し、2014年1月9日よりタシグナ(登録商標)(ニロチニブ)を投与していたが強い副作用が認められたため、5日間で投薬は中止された。
Claims (7)
- 有効成分として、1日あたりの用量5〜20mgの(2S)−2−[(2S,3R)−3−アミノ−2−ヒドロキシ−4−フェニルブタノイルアミノ]−4−メチルペンタン酸又はその薬理学的に許容される塩、ならびに、1日あたりの用量50〜200mgの4−[(4−メチル−1−ピペラジニル)メチル]−N−[4−メチル−3−[[4−(3−ピリジニル)−2−ピリミジニル]アミノ]フェニル]−ベンズアミド又はその薬理学的に許容される塩を含有する、慢性骨髄性白血病の患者を治療又は寛解するための医薬組成物。
- 前記(2S)−2−[(2S,3R)−3−アミノ−2−ヒドロキシ−4−フェニルブタノイルアミノ]−4−メチルペンタン酸又はその薬理学的に許容される塩、及び前記4−[(4−メチル−1−ピペラジニル)メチル]−N−[4−メチル−3−[[4−(3−ピリジニル)−2−ピリミジニル]アミノ]フェニル]−ベンズアミド又はその薬理学的に許容される塩が、1日1〜3回投与されるように用いられることを特徴とする、請求項1に記載の医薬組成物。
- 1日あたりの用量10mgの(2S)−2−[(2S,3R)−3−アミノ−2−ヒドロキシ−4−フェニルブタノイルアミノ]−4−メチルペンタン酸又はその薬理学的に許容される塩、及び1日あたりの用量100mgの4−[(4−メチル−1−ピペラジニル)メチル]−N−[4−メチル−3−[[4−(3−ピリジニル)−2−ピリミジニル]アミノ]フェニル]−ベンズアミド又はその薬理学的に許容される塩が1日1回投与されるように用いられることを特徴とする、請求項1または2に記載の医薬組成物。
- 前記投与が、経口投与である、請求項2または3に記載の医薬組成物。
- 前記患者の尿のpH値が中性からアルカリ性の範囲にある、請求項1〜4のいずれか一項に記載の医薬組成物。
- 前記2つの有効成分が配合剤の形態で含まれる、請求項1〜5のいずれか一項に記載の医薬組成物。
- 前記2つの有効成分がキット製剤の形態で含まれる、請求項1〜5のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016203662 | 2016-10-17 | ||
JP2016203662 | 2016-10-17 | ||
PCT/JP2017/037338 WO2018074409A1 (ja) | 2016-10-17 | 2017-10-16 | 慢性骨髄性白血病を治療又は寛解するための医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2018074409A1 JPWO2018074409A1 (ja) | 2019-06-24 |
JP6691971B2 true JP6691971B2 (ja) | 2020-05-13 |
Family
ID=62019558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018546319A Active JP6691971B2 (ja) | 2016-10-17 | 2017-10-16 | 慢性骨髄性白血病を治療又は寛解するための医薬組成物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20190247338A1 (ja) |
EP (1) | EP3527211B1 (ja) |
JP (1) | JP6691971B2 (ja) |
KR (1) | KR102199253B1 (ja) |
CN (1) | CN109803659A (ja) |
TW (1) | TWI674094B (ja) |
WO (1) | WO2018074409A1 (ja) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
WO2016098546A1 (ja) * | 2014-12-17 | 2016-06-23 | Delta-Fly Pharma株式会社 | 高齢又は末期の癌患者を治療又は寛解するための医薬組成物 |
JP6443682B2 (ja) | 2015-04-15 | 2018-12-26 | カルソニックカンセイ株式会社 | 車両用照明装置およびカップホルダ |
-
2017
- 2017-10-16 JP JP2018546319A patent/JP6691971B2/ja active Active
- 2017-10-16 KR KR1020197009443A patent/KR102199253B1/ko active IP Right Grant
- 2017-10-16 CN CN201780062328.8A patent/CN109803659A/zh active Pending
- 2017-10-16 TW TW106135262A patent/TWI674094B/zh active
- 2017-10-16 US US16/342,429 patent/US20190247338A1/en not_active Abandoned
- 2017-10-16 EP EP17861731.2A patent/EP3527211B1/en active Active
- 2017-10-16 WO PCT/JP2017/037338 patent/WO2018074409A1/ja active Application Filing
-
2019
- 2019-11-14 US US16/684,091 patent/US11185517B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TWI674094B (zh) | 2019-10-11 |
KR102199253B1 (ko) | 2021-01-06 |
CN109803659A (zh) | 2019-05-24 |
TW201817420A (zh) | 2018-05-16 |
US20190247338A1 (en) | 2019-08-15 |
WO2018074409A1 (ja) | 2018-04-26 |
US11185517B2 (en) | 2021-11-30 |
EP3527211B1 (en) | 2023-08-23 |
JPWO2018074409A1 (ja) | 2019-06-24 |
KR20190046937A (ko) | 2019-05-07 |
EP3527211A1 (en) | 2019-08-21 |
US20200078322A1 (en) | 2020-03-12 |
EP3527211A4 (en) | 2020-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3132670A1 (en) | Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment | |
US8492383B2 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
EP3429614B1 (en) | Method of treating triple negative breast cancer | |
JP2024012493A (ja) | 消化管間質腫瘍の治療のための併用療法 | |
JPWO2020080499A1 (ja) | 新規医薬組成物 | |
TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
US11491168B2 (en) | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof | |
JP6691971B2 (ja) | 慢性骨髄性白血病を治療又は寛解するための医薬組成物 | |
JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 | |
US20150051236A1 (en) | Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia | |
JP2023065622A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
KR20210078500A (ko) | 야간 다뇨의 치료 또는 예방제 | |
JP4429732B2 (ja) | 癌の処置におけるグリベック(sti571)とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤 | |
WO2020222302A1 (ja) | 新規医薬組成物 | |
EP4027996A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
WO2021193856A1 (ja) | 腎機能保護剤 | |
JPWO2020080451A1 (ja) | 糖尿病腎症における腎線維化抑制剤 | |
JP2021063014A (ja) | 白血病治療薬 | |
JP2008133271A (ja) | 生活習慣病の予防および/または治療用組成物 | |
NZ625611B2 (en) | Combination treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200331 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200413 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6691971 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |